Outcomes reported for TDF and entecavir as primary antiviral prophylaxis in patients with chronic HBV infection scheduled to receive 6 cycles of R-CHOP-21 for NHL in Ann Arbor stages III or IV
| Study . | Type of study . | No. of patients . | Hematological malignancy . | HBV status (percentage of patients) . | Antiviral prophylaxis . | Follow-up median, mo . | Outcomes reported . |
|---|---|---|---|---|---|---|---|
| This study | Prospective | 39 | DLBCL | HBsAg+ (100) | TDF | 78 | HBV reactivations, 0% |
| HBV DNA+ (31) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Gentile et al14 | Prospective | 11 | Aggressive NHL* | HBsAg+ (100) | TDF | 24 | HBV reactivations, 0% |
| HBV DNA+ (NA) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Choi et al16 | Retrospective | 9 | Aggressive NHL* | HBsAg+ (100) | TDF | 16 | HBV reactivations, 0% |
| HBV DNA+ (100) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Koskinas et al15 | Prospective | 4 | Aggressive NHL* | HBsAg+ (100) | TDF | 18 | HBV reactivations, 0% |
| HBV DNA+ (100) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Huang et al13 | Randomized | 38 | DLBCL | HBsAg+ (100) | Entecavir | 40 | HBV reactivations, 10% |
| HBV DNA+ (NA) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 2.6% | |||||||
| Choi et al, 201416 | Retrospective | 25 | Aggressive NHL* | HBsAg+ (100) | Entecavir | 16 | HBV reactivations, 12% |
| HBV DNA+ (NA) | HBV-related hepatitis, 6% | ||||||
| Chemotherapy disruptions, 2% | |||||||
| Li et al17 | Retrospective | 24 | Aggressive NHL* | HBsAg+ (100) | Entecavir | NA | HBV reactivations, 12% |
| HBV DNA+ (83) | HBV-related hepatitis, 6% | ||||||
| Chemotherapy disruptions, 6% | |||||||
| Kim et al18 | Prospective | 16 | DLBCL | HBsAg+ (100) | Entecavir | 16 | HBV reactivations, 6% |
| HBV DNA+ (100) | HBV-related hepatitis, 4% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Chen et al19 | Retrospective | 4 | Aggressive NHL* | HBsAg+ (100) | Entecavir | 36 | HBV reactivations, 0% |
| HBV DNA+ (50) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% |
| Study . | Type of study . | No. of patients . | Hematological malignancy . | HBV status (percentage of patients) . | Antiviral prophylaxis . | Follow-up median, mo . | Outcomes reported . |
|---|---|---|---|---|---|---|---|
| This study | Prospective | 39 | DLBCL | HBsAg+ (100) | TDF | 78 | HBV reactivations, 0% |
| HBV DNA+ (31) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Gentile et al14 | Prospective | 11 | Aggressive NHL* | HBsAg+ (100) | TDF | 24 | HBV reactivations, 0% |
| HBV DNA+ (NA) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Choi et al16 | Retrospective | 9 | Aggressive NHL* | HBsAg+ (100) | TDF | 16 | HBV reactivations, 0% |
| HBV DNA+ (100) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Koskinas et al15 | Prospective | 4 | Aggressive NHL* | HBsAg+ (100) | TDF | 18 | HBV reactivations, 0% |
| HBV DNA+ (100) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Huang et al13 | Randomized | 38 | DLBCL | HBsAg+ (100) | Entecavir | 40 | HBV reactivations, 10% |
| HBV DNA+ (NA) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 2.6% | |||||||
| Choi et al, 201416 | Retrospective | 25 | Aggressive NHL* | HBsAg+ (100) | Entecavir | 16 | HBV reactivations, 12% |
| HBV DNA+ (NA) | HBV-related hepatitis, 6% | ||||||
| Chemotherapy disruptions, 2% | |||||||
| Li et al17 | Retrospective | 24 | Aggressive NHL* | HBsAg+ (100) | Entecavir | NA | HBV reactivations, 12% |
| HBV DNA+ (83) | HBV-related hepatitis, 6% | ||||||
| Chemotherapy disruptions, 6% | |||||||
| Kim et al18 | Prospective | 16 | DLBCL | HBsAg+ (100) | Entecavir | 16 | HBV reactivations, 6% |
| HBV DNA+ (100) | HBV-related hepatitis, 4% | ||||||
| Chemotherapy disruptions, 0% | |||||||
| Chen et al19 | Retrospective | 4 | Aggressive NHL* | HBsAg+ (100) | Entecavir | 36 | HBV reactivations, 0% |
| HBV DNA+ (50) | HBV-related hepatitis, 0% | ||||||
| Chemotherapy disruptions, 0% |
PubMed, Embase, and Cochrane library databases were searched for articles up to 31 March 2010. All data included in this table are personal extrapolations by the authors based on the features available in each report.
NA, not applicable.
B-cell NHL, not otherwise specified.